Literature DB >> 13295946

Thrombocytopenic purpura in measles.

J B HUDSON, L WEINSTEIN, T W CHANG.   

Abstract

Entities:  

Keywords:  MEASLES/complications; PURPURA, THROMBOPENIC/etiology and pathogenesis

Mesh:

Year:  1956        PMID: 13295946     DOI: 10.1016/s0022-3476(56)80116-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  9 in total

1.  THE PATHOGENESIS OF MEASLES VIRUS INFECTION.

Authors:  C H KEMPE; V A FULGINITI
Journal:  Arch Gesamte Virusforsch       Date:  1965

2.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

3.  Intravenous gamma globulin therapy for thrombocytopenic purpura associated with active varicella infection.

Authors:  T Hara; Y Mizuno; H Igarashi; K Ueda
Journal:  Eur J Pediatr       Date:  1987-09       Impact factor: 3.183

Review 4.  Pathogenesis of rashes in virus diseases.

Authors:  C A Mims
Journal:  Bacteriol Rev       Date:  1966-12

Review 5.  The effects of therapeutic measures in diseases caused by viruses.

Authors:  R P Larke
Journal:  Can Med Assoc J       Date:  1966-11-05       Impact factor: 8.262

6.  Platelet defect of infectious mononucleosis.

Authors:  R Clancy; E Jenkins; B Firkin
Journal:  Br Med J       Date:  1971-12-11

7.  Viral infections of Toronto children during 1965: II. Measles encephalitis and other complications.

Authors:  D M McLean; J M Best; P A Smith; R P Larke; G A McNaughton
Journal:  Can Med Assoc J       Date:  1966-04-23       Impact factor: 8.262

8.  Membrane-bound hemagglutinin mediates antibody and complement-dependent lysis of influenza virus-treated human platelets in autologous serum.

Authors:  M D Kazatchkine; C R Lambré; N Kieffer; F Maillet; A T Nurden
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

9.  Inpatient morbidity and mortality of measles in the United States.

Authors:  Raj Chovatiya; Jonathan I Silverberg
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.